UPDATE - Canaccord Genuity Downgraded United Therapeutics (UTHR) to Hold; Sidelined on Uncertainty

April 27, 2012 11:20 AM EDT
Get Alerts UTHR Hot Sheet
Price: $152.60 -0.55%

Rating Summary:
    8 Buy, 13 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade UTHR Now!
Join SI Premium – FREE
UPDATE - Canaccord Genuity downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold, price target lowered from $56 to $44.

Analyst, Salveen Richter, said, "While the company continues to be a solid cash-generation story, it faces the following challenges: 1) generic threats to Remodulin and Adcirca; 2) the uncertainty of oral treprostinil securing FDA approval in a monotherapy setting on its October 27 PDUFA (one positive P3 monotherapy and two failed P3 combination studies); 3) even if approved, the market potential of oral treprostinil is likely to be limited given physicians’ concern on the magnitude of benefit and their preference for combination use; 4) potential competition from ATLN’s macitentan (P3 SERAPHIN data expected in Q2/12; mortality/morbidity); and 4) a lack of near-term value-driving catalysts."

Lowers FY14 GAAP EPS estimate from $4.89 to $4.21.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades

Add Your Comment